Expert Interview
Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Ticker(s): ICPT, MDGL, NVOInstitution: Texas Liver Institute
- Medical Director and VP of Research and Development at the Texas Liver Institute and Professor of Medicine at the University of Texas Health San Antonio.
- Manages hundreds of patients with NASH.
- Has authored over 400 peer-reviewed publications in medical journals.
Potential for new drug therapies in this space?
Added By: user1ae2bf5fAre combination strategies going to be the best way to treat NASH in the future?
Added By: usera1d398e7Please update us on how field has evolved over past few years.
Importance of liver biopsies for clinical trials and how will this impact commercial opportunities
Has imaging improved ?
Impact of Covid
Which MOA in development is of the highest interest to you and why?
Added By: usera1d398e7Clinical trial failures - Many drugs have flopped in recent years. What have we learned
The GLP-1 agonist Semaglutide had some success and failure in Phase 2 with different stages of disease.
Please provide your interpretation of these conflicting results and your view on potential of this drug class in NASH
Background on clinical practice, how many NASH patients do you manage?
Added By: user1ae2bf5fHow is NASH currently diagnosed and treated?
Added By: user1ae2bf5fAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
